Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...
CNN18d
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro ... while the fourth will make injectable products, the Indianapolis-based drug giant said Wednesday.
AOL10d
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs ... some compounded products aren’t FDA ...
Seeking Alpha22d
Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) which offer obesity/ diabetes drugs, tirzepatide and semaglutide will be competing neck and neck in the GLP-1 market in 2030 with their products ...
FiercePharma18d
With $27B plan to build 4 new plants, Eli Lilly doubles down on US drug manufacturing
In a statement, Ricks also said the investment reflects the company’s “optimism” about its ability to develop pipeline products ... knockoff versions of Lilly’s diabetes and obesity ...